Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Other
Pancrelipase Protease is a critical proteolytic enzyme component of pancreatic enzyme replacement therapy (PERT), used to treat protein malabsorption in patients with exocrine pancreatic insufficiency.
Name
Pancrelipase Protease
Raw Name
PANCRELIPASE PROTEASE
Category
Other
Drug Count
5
Variant Count
30
Last Verified
February 17, 2026
RxCUI
1806919, 1806921, 1806924, 1806926, 1806929, 1806931, 1806964, 1806966, 2478453, 2478455, 2564410, 2564412, 1594671, 1594673, 1595290, 1595292, 1595455, 1595457, 1595460, 1595462, 1595471, 1595473, 1595476, 1595478, 1995477, 1995479, 2669470, 2669472, 1294122, 1294128, 1294481, 1294483, 1543004, 1543006, 1929116, 1929118, 855495, 855499, 855503, 863829, 863836, 863841, 1113042, 1113046, 1373325, 1373327, 1247379, 1247381, 1247386, 1247388
UNII
8MYC33932O, YOJ58O116E, 3560D81V50
About Pancrelipase Protease
Pancrelipase Protease is a critical proteolytic enzyme component of pancreatic enzyme replacement therapy (PERT), used to treat protein malabsorption in patients with exocrine pancreatic insufficiency.
Detailed information about Pancrelipase Protease
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Pancrelipase Protease.
Historically, pancreatic enzymes were used for decades without formal FDA approval as 'grandfathered' drugs. However, in the mid-2000s, the FDA mandated that all manufacturers of pancreatic enzyme products (PEPs) submit New Drug Applications (NDAs) to ensure consistency, safety, and efficacy. Since 2009, several highly regulated brands containing Pancrelipase Protease, such as Creon, Zenpep, and Pancreaze, have received FDA approval. These modern formulations are standardized to contain specific amounts of lipase (for fats), amylase (for starches), and protease (for proteins).
At the molecular level, Pancrelipase Protease consists of several different proteolytic enzymes, including trypsin, chymotrypsin, and carboxypeptidases. These enzymes target specific peptide bonds within protein molecules. When a patient with EPI consumes protein, their lack of endogenous (natural) enzymes prevents the breakdown of these complex molecules. Pancrelipase Protease acts as a substitute, initiating proteolysis in the duodenum (the first part of the small intestine).
Most modern Pancrelipase Protease products are formulated with an enteric coating. This is a crucial pharmacological feature because protease enzymes are proteins themselves and can be denatured (destroyed) by the highly acidic environment of the stomach (pH < 4). The enteric coating allows the enzymes to pass through the stomach intact. Once the medication reaches the more alkaline environment of the duodenum (pH > 5.5), the coating dissolves, releasing the protease to mix with chyme (partially digested food) and begin the catalytic breakdown of dietary proteins.
Unlike most systemic medications, Pancrelipase Protease is not absorbed into the bloodstream. Its action is entirely local within the lumen of the gastrointestinal tract.
Pancrelipase Protease is FDA-approved for the treatment of exocrine pancreatic insufficiency (EPI) associated with various medical conditions, including:
Off-label, healthcare providers may occasionally use Pancrelipase Protease to manage malabsorption in patients with Shwachman-Diamond syndrome or certain types of pancreatic cancer where EPI is a secondary complication.
Pancrelipase Protease is available in several specialized delivery systems:
> Important: Only your healthcare provider can determine if Pancrelipase Protease is right for your specific condition. Because different brands are not bioequivalent (interchangeable), you should not switch brands without medical supervision.
Dosage for Pancrelipase Protease is highly individualized and is usually based on the lipase component of the product, although the protease content is always proportional. According to the Cystic Fibrosis Foundation guidelines and FDA-approved labeling, dosing typically begins with:
For a standard adult, this often translates to 24,000 to 72,000 units of lipase per meal. Your doctor will adjust the dose based on your clinical response, specifically the reduction of steatorrhea (fatty stools) and improvement in nutritional status.
Pancrelipase Protease is approved for use in infants, children, and adolescents. Dosing is strictly weight-based:
Pediatric patients require close monitoring of growth curves and nutritional markers to ensure the dosage is adequate for development.
No dosage adjustment is typically required for patients with kidney disease, as the medication is not systemically absorbed. However, patients with end-stage renal disease should be monitored for hyperuricemia (high uric acid levels).
No dosage adjustment is necessary for patients with liver impairment. The enzymes act locally in the gut and do not require hepatic metabolism.
Clinical trials have not shown significant differences in safety or efficacy between elderly patients and younger adults. Dosing should follow standard weight-based protocols.
If you miss a dose, do not try to 'catch up' by taking it later. Simply skip the missed dose and take your prescribed dose with your next meal or snack. Do not take two doses at once.
While Pancrelipase Protease is not systemically absorbed, extremely high doses can cause significant gastrointestinal distress. Signs of overdose may include severe nausea, vomiting, diarrhea, or high levels of uric acid in the blood (hyperuricemia) and urine (hyperuricosuria). In case of suspected overdose, contact your local poison control center or seek emergency medical attention.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or switch brands without medical guidance, as products are not interchangeable.
Most patients tolerate Pancrelipase Protease well, as it replaces enzymes the body should naturally produce. However, some gastrointestinal side effects are common, especially during the initial titration phase (adjusting the dose):
> Warning: Stop taking Pancrelipase Protease and call your doctor immediately if you experience any of these symptoms:
The primary concern with long-term use of Pancrelipase Protease is the potential for nutritional imbalances if the dose is inadequate, or the risk of colonic strictures (narrowing) if the dose is excessively high over many years. Regular monitoring by a gastroenterologist or cystic fibrosis specialist is required to ensure long-term safety. Because these enzymes are derived from porcine (pig) pancreas, there is a theoretical risk of transmitting viral diseases, although no such cases have ever been documented in decades of use due to rigorous manufacturing and purification processes.
Currently, there are no FDA Black Box Warnings for Pancrelipase Protease products. However, the FDA requires a 'Precautions' section regarding fibrosing colonopathy, which is considered the most significant safety risk associated with the class.
Report any unusual symptoms or changes in bowel habits to your healthcare provider immediately. Regular follow-ups are essential to monitor for both the efficacy of the treatment and any emerging side effects.
Pancrelipase Protease is a porcine-derived product. Patients with a known allergy to pork or pork products should discuss this with their healthcare provider before starting treatment. Additionally, because the enzymes are proteins, they can cause irritation to the mucosal membranes of the mouth and esophagus. Always swallow capsules whole and follow with plenty of water.
No FDA black box warnings for Pancrelipase Protease are currently in effect as of 2026. The safety profile is well-established, provided that dosing remains within the recommended weight-based limits.
Patients taking Pancrelipase Protease require ongoing clinical monitoring to ensure the medication is working and safe:
Pancrelipase Protease does not act on the central nervous system and is not expected to affect your ability to drive or operate heavy machinery. There are no restrictions regarding these activities while taking this medication.
While alcohol does not directly interact with Pancrelipase Protease, alcohol consumption is a leading cause of chronic pancreatitis. Alcohol can further damage the pancreas and worsen the symptoms of exocrine pancreatic insufficiency. Patients are generally advised to avoid or strictly limit alcohol use to prevent further organ damage.
Pancrelipase Protease is typically a lifelong therapy for patients with permanent pancreatic damage (e.g., CF or chronic pancreatitis). Stopping the medication suddenly will result in the return of malabsorption symptoms, including steatorrhea, weight loss, and vitamin deficiencies. There is no withdrawal syndrome, but the underlying condition will remain untreated. Always consult your doctor before making any changes to your medication regimen.
> Important: Discuss all your medical conditions, including any history of intestinal blockage or gout, with your healthcare provider before starting Pancrelipase Protease.
There are no absolute drug-drug contraindications where Pancrelipase Protease must never be used with another medication. However, because it is a digestive enzyme, its efficacy can be significantly altered by medications that change the pH of the gastrointestinal tract.
Pancrelipase Protease does not typically interfere with common blood chemistry or hematology lab tests. However, it will directly affect the results of tests used to diagnose malabsorption, such as:
For each major interaction, the primary management strategy is to maintain a consistent routine and monitor for signs of decreased efficacy (e.g., return of oily stools or weight loss). If you are prescribed a new medication that affects stomach acid (like a PPI or H2 blocker), your doctor may actually use this to increase the effectiveness of your Pancrelipase Protease by ensuring the enzymes reach the small intestine.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for diabetes or stomach acid.
Pancrelipase Protease is contraindicated in a very limited number of circumstances, primarily related to hypersensitivity and acute medical states:
Relative contraindications require a careful risk-benefit analysis by a medical professional:
There is a potential for cross-sensitivity in patients who are allergic to other porcine-derived products, such as certain types of heparin or insulin derived from pigs (though porcine insulin is rarely used today). If you have had a reaction to any animal-derived biological product, inform your doctor.
> Important: Your healthcare provider will evaluate your complete medical history, including any allergies or past surgeries, before prescribing Pancrelipase Protease to ensure it is the safest option for your digestive health.
Pancrelipase Protease is classified as FDA Pregnancy Category C (under the older system). There are no adequate and well-controlled studies in pregnant women. However, untreated exocrine pancreatic insufficiency can lead to severe maternal malabsorption and malnutrition, which poses a significant risk to fetal development. Clinical consensus suggests that Pancrelipase Protease should be used during pregnancy if the nutritional benefits are necessary. Most experts agree that because the enzymes are not absorbed systemically, the risk to the fetus is likely minimal. Healthcare providers should monitor the mother's weight gain and vitamin levels closely throughout the pregnancy.
It is not known whether Pancrelipase Protease enzymes are excreted in human milk. However, since these enzymes are not absorbed into the mother's bloodstream, it is highly unlikely they would appear in breast milk in any significant amount. The nutritional health of the mother is paramount for successful breastfeeding. Most clinicians consider PERT to be compatible with breastfeeding. The infant should be monitored for any unusual changes in bowel habits, though this is rarely an issue.
Pancrelipase Protease is a cornerstone of treatment for children with cystic fibrosis. It is approved for use in all pediatric age groups, including infants. The most critical safety concern in children is the risk of fibrosing colonopathy, which was historically linked to very high doses. It is vital that parents do not exceed the prescribed dose and that the child's growth is monitored by a specialist. For infants, the capsule contents should be mixed with a small amount of acidic food (like applesauce) and given immediately before feeding. Do not mix the enzymes directly into formula or breast milk, as this can degrade the milk proteins and make the enzymes less effective.
Clinical studies have included patients aged 65 and older, and no overall differences in safety or effectiveness have been observed compared to younger patients. However, elderly patients may be more susceptible to constipation, a common side effect of PERT. Additionally, older adults are more likely to have comorbid conditions like gout or renal impairment, which require monitoring of uric acid levels. Polypharmacy (taking multiple medications) is also common in the elderly, so a thorough review of potential interactions with antacids or diabetes medications is necessary.
No specific dose adjustments are provided for patients with renal impairment. However, since Pancrelipase Protease can increase serum uric acid, patients with significant kidney disease (low GFR) are at a higher risk for hyperuricemia and should be monitored closely for signs of gout or uric acid stones.
There is no evidence that hepatic impairment affects the action or safety of Pancrelipase Protease. The medication acts locally in the gut and does not undergo hepatic metabolism. No dose adjustments are required for patients with liver disease or cirrhosis.
> Important: Special populations require individualized medical assessment. Always inform your specialist about your pregnancy status or any underlying kidney or liver conditions.
Pancrelipase Protease acts as an exogenous (external) replacement for the proteolytic enzymes normally secreted by the pancreas. The protease component is a mixture of several zymogens and active enzymes, primarily trypsinogen, chymotrypsinogen, and elastase. In a healthy individual, these are activated in the duodenum by enterokinase. In Pancrelipase products, the enzymes are already in their active or easily activatable forms. They work by catalyzing the hydrolysis of peptide bonds in dietary proteins, breaking them down into oligopeptides and free amino acids. This process is essential for the absorption of nitrogen and the maintenance of muscle mass and overall growth.
The pharmacodynamic effect of Pancrelipase Protease is the reduction of fecal nitrogen excretion and the improvement of protein absorption. The onset of action is rapid—the enzymes begin working as soon as they reach the duodenum and mix with food. The duration of effect is limited to the time the food remains in the small intestine (typically 1 to 4 hours). There is no evidence of tolerance development; the enzymes remain effective as long as they are taken with meals.
| Parameter | Value |
|---|---|
| Bioavailability | 0% (Not absorbed) |
| Protein Binding | N/A (Does not enter circulation) |
| Half-life | N/A (Acts locally) |
| Tmax | N/A (Local action in 30-60 mins) |
| Metabolism | Intestinal autolysis/proteolysis |
| Excretion | Fecal (as digested protein) |
Pancrelipase is a natural product extracted from porcine pancreatic glands. Its molecular formula is complex, as it is a mixture of multiple proteins. The protease component is measured in USP units of activity, defined by the enzyme's ability to digest a standardized casein substrate under specific conditions. It is generally soluble in water and insoluble in alcohol. The enzymes are highly sensitive to heat and pH; they are most stable at a pH of approximately 5.0 to 5.5 and are rapidly inactivated at temperatures above 40°C (104°F).
Pancrelipase Protease is classified as a Pancreatic Enzyme Replacement Therapy (PERT). It is the only therapeutic class approved for the treatment of exocrine pancreatic insufficiency. Related medications include various brand-name formulations like Creon, Zenpep, Pancreaze, Pertzye, and Viokace, which differ in their enzyme ratios and delivery technologies.
Common questions about Pancrelipase Protease
Pancrelipase Protease is primarily used to treat exocrine pancreatic insufficiency (EPI), a condition where the pancreas does not produce enough enzymes to digest food. It is commonly prescribed for patients with cystic fibrosis, chronic pancreatitis, or those who have had pancreatic surgery. By replacing the missing protease enzymes, the medication helps the body break down dietary proteins into amino acids. This prevents malnutrition, muscle wasting, and weight loss. It is an essential therapy for maintaining nutritional health in patients with compromised pancreatic function.
The most common side effects are gastrointestinal in nature, including abdominal pain, bloating, gas, and nausea. Some patients may also experience changes in bowel habits, such as diarrhea or constipation. These symptoms often occur as the body adjusts to the medication or if the dose is not perfectly matched to the patient's diet. Most side effects are mild and can be managed by adjusting the dosage with a healthcare provider. If you experience severe or persistent pain, you should contact your doctor immediately.
While alcohol does not have a direct chemical interaction with Pancrelipase Protease, it is generally discouraged for patients taking this medication. Alcohol consumption is a major cause of chronic pancreatitis and can lead to further damage of the pancreatic tissue. Drinking alcohol can worsen the underlying condition that necessitates the use of enzymes in the first place. Furthermore, alcohol can irritate the digestive tract, potentially complicating the management of malabsorption. It is best to discuss your alcohol consumption habits with your gastroenterologist.
Pancrelipase Protease is generally considered safe during pregnancy because it is not absorbed into the bloodstream and acts only in the digestive tract. However, it is classified as Pregnancy Category C, meaning there is limited clinical trial data in pregnant women. Maintaining proper nutrition is vital for both the mother and the developing fetus, so the benefits of taking the medication usually outweigh any theoretical risks. Pregnant women should be closely monitored by their healthcare team to ensure they are receiving adequate nutrition. Always consult your doctor if you are pregnant or planning to become pregnant.
Pancrelipase Protease begins working almost immediately once it reaches the small intestine and mixes with food. Because it is a digestive aid, it works on a meal-by-meal basis. You should notice an improvement in symptoms like bloating, gas, and oily stools within a few days of starting the correct dose. However, it may take several weeks of dose adjustments to find the optimal level for your specific diet and condition. Long-term benefits, such as weight gain and improved vitamin levels, are usually seen over several months.
You should not stop taking Pancrelipase Protease without consulting your doctor, as it is usually a lifelong replacement therapy. If you stop taking the enzymes, your body will once again be unable to digest proteins and fats properly. This will lead to the immediate return of symptoms like foul-smelling stools, abdominal cramping, and weight loss. Over time, stopping the medication can result in severe malnutrition and vitamin deficiencies. If you are having trouble with the medication, your doctor can help you adjust the dose or switch brands.
If you forget to take your dose with a meal, you can take it if you are still eating or have just finished. If a significant amount of time has passed since your meal, skip the missed dose and take your next dose with your next meal or snack. Do not double the dose to make up for a missed one, as this can increase the risk of side effects like stomach pain. It is helpful to keep a small supply of enzymes with you at all times to ensure you can take them whenever you eat. Consistency is key to managing malabsorption.
Pancrelipase Protease can lead to weight gain, but this is generally a positive and intended effect of the medication. Patients with pancreatic insufficiency often lose weight because they cannot absorb nutrients from their food. By helping the body digest protein and other nutrients, the medication allows patients to regain lost weight and maintain a healthy body mass. It does not cause 'unhealthy' weight gain or fat accumulation in the way some other medications might. If you experience sudden or excessive weight gain, discuss it with your healthcare provider.
Yes, Pancrelipase Protease can be taken with most other medications, but some interactions require attention. For example, antacids can sometimes interfere with the coating of the enzymes, causing them to release too early. Conversely, doctors often prescribe proton pump inhibitors (PPIs) to help the enzymes work better by reducing stomach acid. It can also interact with certain diabetes medications like acarbose. Always provide your doctor with a full list of all prescriptions, over-the-counter drugs, and supplements you are taking to ensure safe use.
Currently, Pancrelipase Protease is not available as a true generic in the way many other drugs are. Because these are complex biological products derived from animal tissue, the FDA considers them 'biologics' rather than simple chemicals. Different brands (like Creon, Zenpep, and Pancreaze) are not considered bioequivalent, meaning they cannot be automatically substituted for one another at the pharmacy. You should always stay on the specific brand prescribed by your doctor. If your insurance requires a change, your doctor must write a new prescription for the different brand.